Sugi Predict

Sugi Predict / Compounds / SCHEMBL18850

SCHEMBL18850

SCHEMBL18850

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)[C@@H](CO)C1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.51
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PARP1 P09874 2/20 0.41
▸ HPGD P15428 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ SETD7 Q8WTS6 1/20 0.39
▸ KAT7 O95251 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1184434 1.00 NR1H2 (0.51) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL780271 1.00 NR1H2 (0.51) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL22168000 0.93 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL22168285 0.93 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL16931340 0.91 NR1H2 (0.49) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL20541079 0.91 NR1H2 (0.46) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL31297386 0.91 NR1H2 (0.49) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL30111484 0.91 NR1H2 (0.46) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL1944901 0.91 NR1H2 (0.49) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL28942832 0.91 NR1H2 (0.49) NR1H2MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025064683-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-20 — — US disclosed
US-20230348462-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2023-11-02 — — US disclosed
EP-4240741-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS Deutsches Krebsforschungszentrum (DE) 2023-09-13 — — EP disclosed
US-20220227738-A1 KRAS G12C INHIBITORS AND USES THEREOF CALIFORNIA INSTITUTE OF TECHNOLOGY 2022-07-21 — — US disclosed
WO-2022115439-A1 KRAS G12C INHIBITORS AND USES THEREOF CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-06-02 — — WO disclosed
WO-2022115439-A1 KRAS G12C INHIBITORS AND USES THEREOF CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-06-02 — — WO disclosed
WO-2022096361-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2022-05-12 — — WO disclosed
EP-3992191-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS Deutsches Krebsforschungszentrum (DE) 2022-05-04 — — EP disclosed
EP-3972978-A1 KRAS G12C INHIBITORS AND USES THEREOF CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-03-30 — — EP disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 — — US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 — — US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 — — WO disclosed
US-20110059969-A1 PIPERAZINES AS ANTI-OBESITY AGENTS ASTRAZENECA AB (SE) 2011-03-10 — — US disclosed
US-20110046135-A1 NEW COMPOUNDS I ASTRAZENECA AB (PUBL) (SE) 2011-02-24 — — US disclosed
US-7851471-B2 Compounds I ASTRAZENECA AB (PUBL) (SE) 2010-12-14 — — US disclosed
EP-2229362-A1 PIPERAZINES AS ANTI-OBESITY AGENTS AstraZeneca AB (SE) 2010-09-22 — — EP disclosed
US-20090181967-A1 New compounds I BIOVITRUM AB (SE) 2009-07-16 — — US disclosed
WO-2009071658-A1 PIPERAZINES AS ANTI-OBESITY AGENTS BIOVITRUM AB (PUBL) (SE) 2009-06-11 — — WO disclosed
WO-2002012185-A1 PROCESS FOR PREPARING 2,3-DIAMINOPROPANOLS AND SYNTHESIS OF OTHER COMPOUNDS USING 2,3-DIAMINOPROPANOLS CHEMBIONEX CO., LTD. (KR) 2002-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250091989-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS NR1H2 3045/4885MEN1 867/4885ALDH1A1 2774/4885
US-20230348462-A1 IMIDAZO[4,5-C]QUINOLINE COMPOUNDS AND THEIR USE AS ATM KINASE INHIBITORS ATM, CHEK2, CHEK1 NR1H2 2104/4885MEN1 2251/4885ALDH1A1 4047/4885
US-20090181967-A1 New compounds I GPR119, GLP1R, FABP4 NR1H2 66/4885MEN1 1944/4885ALDH1A1 2089/4885
US-20110046135-A1 NEW COMPOUNDS I GPR119, GLP1R, FABP4 NR1H2 66/4885MEN1 1944/4885ALDH1A1 2089/4885
US-20220227738-A1 KRAS G12C INHIBITORS AND USES THEREOF KRAS, NRAS, HRAS NR1H2 2326/4885MEN1 408/4885ALDH1A1 2497/4885
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 NR1H2 1489/4885MEN1 4072/4885ALDH1A1 3293/4885
US-20110059969-A1 PIPERAZINES AS ANTI-OBESITY AGENTS GPR119, FABP4, ADIPOR2 NR1H2 145/4885MEN1 4212/4885ALDH1A1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.